Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Opioid-free Pain relief for Enhanced Recovery After Spine fixation surgery

Project description

Non-opioid pain relief after major surgery

There is a significant shortage of safe and effective pain treatments after major surgery. Especially after spine fixation procedures, many patients endure debilitating pain for several days, now treated with opioids. However, with their harmful side-effects and highly addictive properties, opioids often provide insufficient pain relief. Therefore, to promote early recovery and discharge, SentryX is developing an innovative non-opioid local pain treatment called Bupi-Ring. Designed for spine fixation surgery, it is easily co-implanted with existing surgical screws with minimal change to the surgical workflow. Once in place, Bupi-Ring delivers an approved local anaesthetic for 72+ hours before dissolving in the body. The EIC-funded OPERAS project will evaluate the safety and efficacy of Bupi-Ring in humans for the first time.

Objective

There is a troubling lack of effective pain treatments after major surgery. Especially after musculoskeletal procedures, patients experience debilitating pain now treated with opioids. Opioids provide insufficient pain relief, have many toxic side-effects, and are highly addictive. Pain and opioid-related side-effects impede early mobilisation and recovery and are the primary reasons for extended hospital stays.
SentryX is developing revolutionary drug delivery technology to extend the effects of a well-established local pain blocker called bupivacaine. Its initial use case in spine fixation surgery, Bupi-Ring, delivers bupivacaine directly to the surgical site for more than 72 hours without changing the existing surgical workflow. Non-opioid local pain relief in this critical early phase of recovery will promote early mobilisation, shorten hospital stays, prevent complications, and save costs. This project will demonstrate Bupi-Ring’s safety and efficacy in humans for the first time.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

SENTRYX BV
Net EU contribution
€ 2 500 000,00
Address
WOUDENBERGSEWEG 41
3711 AA AUSTERLITZ
Netherlands
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 5 687 678,50